Invest in intelligence that delivers

Spherix Market Expertise

Our team of experts and physician
community give you a competitive edge.

See the market from the prescribers’ point of view.

Our physician community includes direct relationships with our curated physician network and leading KOLs, who keep us closely connected with the specific challenges of specialty markets.

Vetted Practicing Physicians

Key Opinion Leaders

Professional Organizations

3,300+ members in the Spherix US Physician Community

Our therapeutic experts are always just a click or call away...

  • Plugged into the ever-evolving landscape
  • Ready to provide an unbiased view of the landscape
  • Insightfully answer real-time questions
  • Highlight opportunities 
  • Identify disruptors

Dermatology

Expertise

7

dedicated team members

11

years of
continuous tracking

25

studies published annually

Indications

  • Alopecia Areata (AA)
  • Asthma
  • Atopic Dermatitis (AD)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Chronic Spontaneous Urticaria (CSU)
  • Hidradenitis Suppurativa (HS)
  • Plaque Psoriasis (PsO)
  • Prurigo Nodularis (PN)
  • Vitiligo

Team Lead

Andy Stankus
Franchise Head, Dermatology

Andy, with a pharmaceutical marketing MBA, has 27+ years of experience in life sciences and healthcare consultancy creating commercial strategy, differentiation and real-world value.  Prior to Spherix, Andy led global product launches at Johnson & Johnson, data and research consulting teams at Kantar Health / Oracle Life Sciences, and enjoys publishing and speaking across multiple therapeutic areas at international conferences.  In addition to this broad therapeutic expertise, given a specific passion in dermatology, Andy and teams he has led have been lead authors on more than 145 dermatology publications across 20+ life sciences organizations.

Gastroenterology

Expertise

7

dedicated team members

11

years of
continuous tracking

25

studies published annually

Indications

  • Celiac Disease
  • Cholestatic Pruritus
  • Crohn’s Disease
  • Eosinophilic Esophagitis
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome
  • Metabolic Dysfunction–Associated Steatohepatitis (MASH)
  • Obesity
  • Primary Biliary Cholangitis
  • Ulcerative Colitis

Team Lead

Jim Hickey
Franchise Head, Gastroenterology

Jim has 20+ years’ experience building and leading research teams, pioneering innovative research techniques, and providing insight solutions to pharmaceutical brands. Prior to Spherix, he led the research team at Verilogue from early startup through its acquisition by Publicis Health. Jim has extensive experience across a wide range of therapeutic categories and a particular interest in gastroenterology and inflammatory disease.

Rheumatology

Expertise

7

dedicated team members

11

years of
continuous tracking

24

studies published annually

Indications

  • Ankylosing Spondylitis and nr-AxSpA
  • Cutaneous Lupus (CLE)
  • Giant Cell Arteritis (GCA)
  • Idiopathic Inflammatory Myopathies (IIM)
  • Lupus Nephritis
  • Psoriatic Arthritis (PsA)
  • Rheumatoid Arthritis
  • Sjogren’s Disease
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)

Team Lead

Lynn Price
Franchise Head, Rheumatology

Lynn has over eight years at Spherix, leading
strategic initiatives and insights development.
She previously, directed research analytics at
Decision Resources Group and managed
immunology research at BioTrends, with
extensive experience in data analysis and
client relations in the biopharmaceutical
sector.

Nephrology

Expertise

8

dedicated team members

11

years of
continuous tracking

25

studies published annually

Indications

  • Chronic Kidney Disease, Non-Dialysis (CKD-ND)
  • Complement Disorders
  • Complement 3 Glomerulopathy (C3G)
  • Dialysis
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Hyperphosphatemia (HPhos)
  • IgA Nephropathy (IgAN)
  • Membranous Nephropathy (MN)
  • Renal Anemia
  • Transplant/AMR

Team Lead

Kari McCarthy
Franchise Head, Nephrology

Kari has more than 20 years of experience in healthcare, strategy and insights, with a strong track record in brand development, market research, and strategic narrative building. Most recently, Kari was the VP of Strategy at DDB Health, where she led brand strategy for nephrology and oncology brands. 

CNS

Expertise

7

dedicated team members

11

years of
continuous tracking

18

studies published annually

Indications

  • Alzheimer’s Disease
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Epilepsy
  • Generalized Myasthenia Gravis (gMG)
  • Major Depressive Disorder
  • Migraine
  • Multiple Sclerosis (MS)
  • Schizophrenia

Team Lead

Bob Shewbrooks

Franchise Head, CNS

Bob has over 25 years of industry experience, having held roles at Wyeth (Pfizer), Otsuka, and Sumitomo, supporting business units and brands. He brings significant experience on the supplier side in consulting, as well as primary and syndicated market research, driving growth and innovation across portfolios.

Ophthalmology

Expertise

7

dedicated team members

4

years of
continuous tracking

9

studies published annually

Indications

  • Age-Related Macular Degeneration (AMD)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy

Team Lead

Bob Shewbrooks

Franchise Head, Ophthalmology

Bob has over 25 years of industry experience, having held roles at Wyeth (Pfizer), Otsuka, and Sumitomo, supporting business units and brands. He brings significant experience on the supplier side in consulting, as well as primary and syndicated market research, driving growth and innovation across portfolios.

Hematology/Oncology

6

dedicated team members

3

years of
continuous tracking

10

studies published annually

Indications

  • Acute Myeloid Leukemia (AML)
  • B-Cell Malignancies
  • Bleeding Disorders
  • Chronic Lymphocytic Leukemia (CLL)
  • Hemophilia A & B
  • Immune Thrombocytopenic Purpura (ITP)
  • Large B-Cell Lymphoma (LBCL)
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Sickle Cell Disease (SCD)
  • Smoldering Myeloma
  • Solid Tumors
  • Thalassemia (Thal)
  • Von Willebrand Disease (VWD)
  • Warm Autoimmune Hemolytic Anemia (wAIHA)

Team Lead

Sarah Hendry

Franchise Head, Hematology/Oncology

Sarah has over a decade of experience managing custom and syndicated projects, specializing in hematology/oncology.  She brings deep expertise in brand strategy and patient-centered communications within healthcare and pharma. Most recently, Sarah led brand strategy execution for CAR-T therapies at DDB Health, working closely with pharmaceutical partners to enhance engagement and brand growth. In her previous research roles at Verilogue and Maslansky + Partners, she worked extensively in hematology, including co-authoring an article in the Orphanet Journal of Rare Diseases on the lexicon for gene therapy in hemophilia B, communicating the complement cascade in PNH, and analyzing market dynamics in myeloma and B-cell malignancies.

Sign up for alerts, market insights and exclusive content in your inbox.